Articles On Hera Med (ASX:HMD)

The ASX 200 has finished the day in the red but is still above 7,000 points. The ASX 200 shed 0.68 per cent closing at 7,018 points while the ASX Emerging Companied Index fell 0.33 per cent, closing at 2,101 points. All sectors were in the...

The official publication of the American College of Obstetricians and Gynecologists has endorsed the results of a clinical trial into HeraMED’s foetal monitoring device. HeraMED (ASX:HMD) is a step closer to commercialisation following the...

Source:New Africa ,Shutterstock Summary COVID-19 had a significant impact on the HeraMED’s and Adherium’s first half 2021 results. However, the two players made critical developments during the period. HeraMED plans to expand further...

Summary With COVID-19 giving the opportunity to develop products, enhance services and conduct R&D, healthcare sector will be vigilantly gauged. Early spotting of a winning penny stock can offer considerable rewards to patient and...

Summary Amid growing adoption of digital platforms, Global Health registered a robust half-year performance. Total customer revenue for the period was up by 20% on PCP. The MasterCare platform for community health care providers exper...

Summary Global Health Ltd (ASX:GLH) said Lifecard Patient Portal is seeing high demand as health delivery organisations have embraced digital engagement with patients. Lifecard Patient Portal assists consumers and doctors in managing d...

Summary HeraMED’s partnership with eCare21 aims to fast-track awareness of HeraCARE and HeraBEAT across the US. Dimerix drug compound DMX-200 is set to be tested for COVID-19-induced ARDS in the global study. Dimerix is confident that...

Maternity-focused technology start-up HeraMED (ASX: HMD) has signed an agreement with US virtual care provider eCare21 to integrate its smart pregnancy monitoring solutions into eCare21’s software-as-a-service (SaaS) platform. Under the agr...

Special Report: Maternity health digitiser HeraMED has raised serious cash from new and existing sophisticated and institutional investors to speed the rollout of its software platform HeraCARE. HeraMED (ASX:HMD) has raised $2.32m to speed...

Special Report: Maternal health tech company HeraMED is preparing for clinical trials in Australia with a new partnership. HeraMED (ASX:HMD) is getting ready to run clinical trials for its maternity care telehealth and remote monitoring so...

Special Report: Medical tech company HeraMED has signed an exclusive deal to distribute its foetal heart rate monitors in Australia. HeraMED (ASX:HMD) is accelerating its commercialisation strategy with an exclusive two-year Australian dist...

As we approach the middle of 2020, the investment environment surrounding the fallout from the COVID-19 pandemic remains complex. Along with threats, there will be plenty of opportunities. And it’s against that backdrop that this week marke...

VidCon is Stockhead’s new virtual conference series, bringing you expert insights, panel discussions and presentations on the most interesting and relevant investment sectors from leading analysts, listed small caps and industry participant...

Seasoned financial advisor, investment manager and corporate director Dr Nigel Finch is back in the radio booth for another instalment of The StockDoc Podcast. In this episode the good doctor sits down with Alexander Radke, general manager...

Stock Talk is a new Stockhead video series featuring a roundtable of experts discussing a new investment topic each week. In this first edition, host Dr Nigel Finch examines the coronavirus-induced boom of the telehealth industry. Populatin...

Maternity telehealth company HeraMED (ASX: HMD) revealed this morning in a conference call it was in “advanced discussions” regarding the expedited commercial roll-out of its platform across the US, UK, Australia and Israel. The company’s H...

HeraMED Limited (ASX:HMD), a medical technology company leading the digital transformation of maternity care with its proprietary in-home maternity care platform, advised on Tuesday morning that it had received a significant uplift in inter...

The coronavirus-induced market carnage of the last few weeks has rattled plenty of investor nerves. But as with any major correction, some industries feel the brunt of the impact while for others, the dramatic shift presents an opportunity....

Special Report: HeraMed’s fast-tracked development process has paid dividends as its flagship product nears pilot testing. Medical technology company HeraMED’s (ASX:HMD) proprietary hybrid maternity care platform, HeraCARE, is now fully fu...

Another ASX small cap has won the blessing of the Food and Drug Administration (FDA) for its products enter the US market. This morning it was Compumedics (ASX:CMP). Its signature product, the Orion LifeSpan Magnetoencephalography single De...

HeraMED (HMD) has appointed Alexander Radke as General Manager of its U.S. operations Alexander has previously held senior roles and has vast experience in the U.S. healthcare market He will use his expertise to develop the company’s strat...

2020 could be the year HeraMED (ASX:HMD) comes of age and it all has to do with its Artificial Intelligence (AI) platform, a cloud based machine learning software-as-a-service (SaaS) platform, known as OrionAI.

HeraMED (HMD) has received roughly 90,000 pregnancy monitoring records from the Mayo Clinic via their recent collaboration This is key in progressing the Orion AI platform, a cloud-based platform that analyses pregnancy records and detects...

Medical technology company, HeraMED Limited (ASX:HMD) has received approximately 90,000 pregnancy records from research and development collaborator the Mayo Clinic, which will be implemented into its OrionAI platform. This provides HeraMED...

Australian health care sector is one of the fastest growing, dynamic and highly diversified sectors having enormous potential to generate substantial returns for the Australian economy. A broad range of companies, from companies engaged in...

Technology undoubtedly holds a significant importance in each sector of the industry, more so than ever, and certainly health care sector is no different. Use of technologies in the health care sphere has emerged as a boon for doctors, rese...

Medical technology company, HeraMED Limited (ASX:HMD) is pursuing verification around the potential for its HeraBEAT and HeraCARE solutions to be reimbursed under the US reimbursement code system. Should this occur, under new CPT (Current P...

The Mayo Clinic has been established for more than 150 years, and employs more than 4500 physicians and scientists along with 54,000 allied health staff across 19 hospitals in five US states. It has been ranked No 1 hospital in the world fo...

Technology certainly plays a significant role in each segment of the industry, more so than ever, and health care sector is no different. Introduction of technologies in the health care domain emerged as the biggest blessing not only for pa...

Medical technology group, HeraMED Limited’s (ASX:HMD) distributor based in India has secured a commercial service partnership with Cloudnine Hospital Group to initiate a commercial pilot allowing expecting mothers in the Cloudnine network t...

HeraMED (ASX:HMD) has signed an agreement with Kinderheldin to add online midwifery service to be offered as HeraBEAT PLUS in Germany.

The good news keeps flowing for medical technology company, HeraMED Limited (ASX:HMD) with the company announcing today that it has entered into an agreement with leading midwife service provider, Kinderheldin GmbH. This follows news earlie...

HeraMED’s (ASX:HMD) foetal ultrasound heart rate monitor has got its long awaited green light to enter the US market and it has doubled in just a few days. The US Food and Drug Administration has approved its 510(k) application meaning it c...

Medical technology company, HeraMED Limited’s (ASX:HMD) 510(k) application (K191110) for the company’s HeraBEAT US foetal ultrasonic heart rate monitor (HeraBEAT US) has been cleared by the US Food and Drug Administration (FDA). The FDA eva...

Medical data and technology developer HeraMED (ASX: HMD) has been granted key regulatory approval for its foetal ultrasonic heart rate monitor in the US after undergoing a premarket review process for the past 6 months. The US Food and Drug...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Each Monday, Stockhead recaps which stocks are most heavily in demand by investors — running hot. The analysis is based on the Relative Strength Index (RSI), a technical gauge which measures how trading momentum is affecting the price actio...

With a vision to revolutionize the pregnancy ecosystem HeraMED Limited (ASX: HMD) – an innovative medical technology startup, provides smart pregnancy monitoring solutions for home use, against the problems associated with the reliability o...

Yesterday was an interesting day on the markets for HeraMED (ASX:HMD), the medtech platform which makes pregnancy-monitoring devices. The stock has been trading in a range between 15c and 17c in recent months. And strategically, it’s been c...

Medical technology group HeraMED Limited (ASX:HMD) has gone from strength to strength since listing on the ASX in December 2018, excelling in the area of product development and distribution, but also forging alliances with high profile med...

HeraMED (ASX:HMD) has a target market of 2 million pregnancies in 2020, 6 million in 2021 and 45 million in 2022.

Medical company Next Science (ASX:NXS) reiterated its US market focus in an investor presentation this morning. The company forecast continued revenue growth in the 2020 financial year, led by sales of its non-toxic Xbio formulations which...

Medicinal cannabis stock Althea (ASX:AGH) had a mixed bag of news for investors in its market update this morning. The company said patient numbers for its prescription medicinal cannabis products in Australia are on track to reach 4,000 by...

Australia’s Healthcare Sector is recognised as one the best in the world with significant advances in technology that help provide better ways of delivering healthcare services. However, the sector is also prone to a number of challenges li...

Time is dynamic. Business is dynamic. Change might be the only constant factor but surprisingly for the Aussie share market, some events and statuses have remained intact over the past century. A 100 years is a really long period, and to ha...

CV Check Ltd CV Check Ltd (ASX: CV1) is a leading online integrated screening and verification company which offers check products to employers, industry associations and individual customers through the CVCheck brand on its proprietary web...